PDS Biotechnology (NASDAQ:PDSB) Stock Price Down 5.9% – Here’s What Happened

PDS Biotechnology Corporation (NASDAQ:PDSB)’s stock price traded down 5.9% during mid-day trading on Wednesday . The company traded as low as $0.7102 and last traded at $0.7155. 108,284 shares were traded during trading, a decline of 67% from the average daily volume of 330,208 shares. The stock had previously closed at $0.76.

Analysts Set New Price Targets

Several research firms recently issued reports on PDSB. Wall Street Zen upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of PDS Biotechnology in a report on Friday, July 17th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

The firm has a market cap of $40.01 million, a P/E ratio of -1.07 and a beta of 1.59. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 2.73. The business has a 50-day moving average of $0.97 and a two-hundred day moving average of $0.89.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Wednesday, May 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, sell-side analysts anticipate that PDS Biotechnology Corporation will post -0.52 earnings per share for the current fiscal year.

Institutional Trading of PDS Biotechnology

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in PDS Biotechnology by 25.0% during the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock worth $134,000 after buying an additional 44,100 shares during the last quarter. Virtu Financial LLC bought a new position in shares of PDS Biotechnology during the 4th quarter valued at approximately $25,000. Armistice Capital LLC purchased a new stake in PDS Biotechnology in the 4th quarter worth about $2,182,000. Commonwealth Equity Services LLC grew its stake in PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after buying an additional 106,300 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of PDS Biotechnology by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after buying an additional 38,399 shares during the period. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical?stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen?presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS?0101, is designed to treat HPV16?positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV?focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.